Institute for Molecular Medicine

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Institute for Molecular Medicine sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).

2 total trials 1 currently recruiting early-phase tilt upper half by trial count

Institute for Molecular Medicine: 2 sponsored US clinical trials, 1 recruiting.

Institute for Molecular Medicine sponsors 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Alzheimer Disease, with 1 trials.

Mid-pack sponsor footprint

Institute for Molecular Medicine is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

What is open in the Institute for Molecular Medicine pipeline

1 recruiting of 2 indexed (50% open).

Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).

Top condition: Alzheimer Disease (1 trial), 0 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Institute for Molecular Medicine: open-pipeline peers nationwide

Peers matched on 2 registered trials and 50% open enrollment, not the therapeutic-area sidebar.

Institute for Molecular Medicine sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1.522.533.544.5 0%20%40%60% Total trials Recruiting share Institute for Molecular Medicine1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO Health3ive Labs60 Degrees Pharmaceuticals7 Hills PharmaAbcentra
Institute for Molecular Medicine sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Institute for Molecular Medicine sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 2 trials (± recruiting share)

Sponsors near 50% open enrollment (± trial volume)

What to do with this Institute for Molecular Medicine page

2 registered trials is a research-attention snapshot, not an endorsement of Institute for Molecular Medicine or any single study.

  • 1 of Institute for Molecular Medicine's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Alzheimer Disease is the condition Institute for Molecular Medicine studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Alzheimer Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Institute for Molecular Medicine pipeline card: 2 registered trials from official public datasets.Report a data error.